share_log

Pfizer | 8-K: Pfizer's Financial Results for the Second Quarter of 2024

Pfizer | 8-K: Pfizer's Financial Results for the Second Quarter of 2024

輝瑞 | 8-K:2024年第二季度的財務業績
美股sec公告 ·  07/30 08:05
Moomoo AI 已提取核心訊息
On July 30, 2024, Pfizer Inc. released its financial results for the second quarter of 2024. The announcement was made through a press release, which is now available as Exhibit 99. This information, while furnished to the Securities and Exchange Commission (SEC) in a Form 8-K filing, is not considered filed for Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any of Pfizer's other filings, unless explicitly stated. The press release provides detailed insights into Pfizer's operational and financial performance for the quarter.
On July 30, 2024, Pfizer Inc. released its financial results for the second quarter of 2024. The announcement was made through a press release, which is now available as Exhibit 99. This information, while furnished to the Securities and Exchange Commission (SEC) in a Form 8-K filing, is not considered filed for Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any of Pfizer's other filings, unless explicitly stated. The press release provides detailed insights into Pfizer's operational and financial performance for the quarter.
2024年7月30日,輝瑞公司公佈了2024年第二季度的財務業績。該公告發布在展品99中,展品已發佈爲新聞稿。儘管這些信息以8-k表格形式提交給了證券交易委員會(SEC),但不被視爲根據《1934年證券交易法》第18條規定提交併不被納入輝瑞的任何其他提交中,除非有明確說明。新聞稿提供了有關輝瑞第二季度運營和財務表現的詳細信息。
2024年7月30日,輝瑞公司公佈了2024年第二季度的財務業績。該公告發布在展品99中,展品已發佈爲新聞稿。儘管這些信息以8-k表格形式提交給了證券交易委員會(SEC),但不被視爲根據《1934年證券交易法》第18條規定提交併不被納入輝瑞的任何其他提交中,除非有明確說明。新聞稿提供了有關輝瑞第二季度運營和財務表現的詳細信息。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息